Savira seeks to partner its comprehensive IPR portfolio on influenza polymerase inhibitors targeting the virus’ cap snatching mechanism.
The portfolio comprises
a) enabling technologies claiming methods for identifying novel compounds based on polypeptides containing the active site of cap-binding and endonuclease domains of the influenza virus.
b) broad portfolio of composition of matter patents claiming various structural classes for cap-binding and endonuclease inhibitors with recent priority dates.
The most promising development candidates (cap-binding and endonuclease inhibitors) proved highly potent in challenge studies in mice and suggest clinical candidate potential.